Health / Medical Topics |
yttrium Y 90 clivatuzumab tetraxetan
Pronunciation
A substance being studied in the treatment of advanced pancreatic cancer. Yttrium Y 90 clivatuzumab tetraxetan contains a monoclonal antibody that binds to a protein called MUC-1, which is found on some pancreatic cancer cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90 clivatuzumab tetraxetan is a type of radioimmunoconjugate. Also called yttrium Y 90 DOTA monoclonal antibody HuPAM4. (NCI Dictionary)
YOU MAY ALSO LIKE
A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or…
A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the…
A radioimmunoconjugate consisting of the murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90 with potential radioimmunotherapeutic activity. Yttrium Y 90…
A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y…
A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal…
A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic…